FDA has approved ibrutinib (Imbruvica) for adult patients with chronic graft versus host disease after failure of one or more lines of systemic therapy, making it the first FDA-approved therapy for the treatment of cGVHD.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
